Vial

Dr. Scott Kahan, Director of the National Center for Weight and Wellness at Johns Hopkins Bloomberg School of Public Health, highlights the importance of new mechanisms of action beyond GLP-1 therapies. These innovative approaches - targeting muscle, fat, and liver cells - could help people who currently don’t respond to or can’t tolerate existing medications. Discover Vial’s INHBE program: https://lnkd.in/ghEUN_kE

Obesity care is evolving - and so is the science behind it. Dr. Lee Kaplan, Director at Dartmouth Health's Weight and Wellness Center, points to the myostatin/activin pathway as a promising target. Vial’s INHBE is at the forefront of this research, with potential to enhance fat loss while preserving lean mass, opening new possibilities for patients and clinicians alike. More here: https://lnkd.in/ghEUN_kE

It’s clear the next breakthrough in obesity treatment will come from entirely new mechanisms that go beyond appetite suppression like VIAL-INHBE. Hear more from Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research. VIAL-INHBE: https://lnkd.in/ghEUN_kE

Our team had a fantastic week connecting with biotech leaders and innovators shaping the future of medicine in Vienna. If we didn’t get a chance to connect, we’d still love to hear from you — get in touch here: https://lnkd.in/gMnXcWxR

VIAL-INHBE’s selective fat reduction and muscle preservation is a profile with meaningful clinical potential. Dr. Massimo Volpe, Professor of Cardiology at Sapienza Università di Roma, shares his perspective on why this approach could transform patient care. More about VIAL-INHBE here: https://lnkd.in/ghEUN_kE

BIO-Europe 2025 starts today! The Vial team is on site and excited to share updates on our pipeline, including our INHBE (Activin E) program. Connect with us through the BIO One-on-One Partnering™ platform or reach out directly: https://lnkd.in/g-nZi6RU

Dr. Jason Fung: Treating obesity means more than weight loss - it’s about correcting metabolic disease. VIAL-INHBE can help obese and overweight populations avoid major health issues. Discover Vial’s INHBE program: https://lnkd.in/ghEUN_kE

Vial’s Phase I for INHBE (Activin E) siRNA program for the treatment of obesity and other cardiometabolic diseases has been initiated. https://lnkd.in/g--6w6bR

Vial has initiated a Phase I for Vial’s INHBE (Activin E) siRNA program for treatment of obesity. Check our website to learn more: https://lnkd.in/gMSfk6V9

Vial has initiated a Phase 1 for Vial’s INHBE (Activin E) siRNA for obesity. The Vial team is proud to mark this milestone as we continue advancing new options for patients with obesity. Read the full press release: https://lnkd.in/g--6w6bR